Comparative Pharmacology
Head-to-head clinical analysis: METHYLIN ER versus MODAFINIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHYLIN ER versus MODAFINIL.
METHYLIN ER vs MODAFINIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylphenidate is a central nervous system stimulant that blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their availability in the synaptic cleft.
The precise mechanism of action is unknown. Modafinil is a wakefulness-promoting agent that may have direct or indirect effects on dopamine, norepinephrine, serotonin, GABA, glutamate, and orexin systems. It binds to the dopamine transporter and inhibits dopamine reuptake.
20-60 mg orally once daily in the morning
200 mg orally once daily in the morning.
None Documented
None Documented
Mean 3-6 hours in adults; longer in children (4-8 hours). Clinical context: steady-state reached within 2 days; dosing every 8-12 hours.
Clinical Note
moderateArmodafinil + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Armodafinil."
Clinical Note
moderateModafinil + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Modafinil."
Clinical Note
moderateModafinil + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Modafinil."
Clinical Note
moderateModafinil + Erythromycin
Terminal elimination half-life is approximately 15 hours (range 10–30 hours). This supports once-daily dosing for sustained wakefulness.
Renal (90% as metabolites, <1% unchanged). Biliary/fecal: <2%.
Primarily renal (as metabolites and unchanged drug); approximately 80% of the dose is recovered in urine, with less than 10% as unchanged modafinil. Fecal excretion accounts for less than 1%.
Category C
Category C
CNS Stimulant
CNS Stimulant
"The metabolism of Erythromycin can be decreased when combined with Modafinil."